Orphan Drugs Global Market Report 2025

Description

Orphan drugs are medications specifically formulated to address uncommon medical conditions. These drugs are designed to meet public health needs that are often neglected by the pharmaceutical industry due to financial constraints. The term ""orphan"" in this context refers to medications that may have been developed for a common condition but are also effective in treating a less prevalent medical issue.

Orphan drugs come in two main types biological and non-biological. They are employed in various therapeutic areas, including oncology, hematology, neurology, cardiovascular, respiratory, and immunomodulatory applications. Hematology specifically focuses on the study of blood and blood-related disorders. The distribution of these drugs is carried out through hospital pharmacies, retail pharmacies, and online sales.

The orphan drugs market research report is one of a series of new reports from The Business Research Company that provides orphan drugs market statistics, including orphan drugs industry global market size, regional shares, competitors with an orphan drugs market share, detailed orphan drugs market segments, market trends and opportunities, and any further data you may need to thrive in the orphan drugs industry. This orphan drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orphan drugs market size has grown rapidly in recent years. It will grow from $188.45 billion in 2024 to $208.04 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to orphan drug act of 1983, rising interest in rare diseases, drug repurposing, advancements in genetic understanding, research funding initiatives.

The orphan drugs market size is expected to see exponential growth in the next few years. It will grow to $481.69 billion in 2029 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to evolving market access policies, value-based healthcare initiatives, global market expansion, patient-centric drug development, targeting rare cancers. Major trends in the forecast period include increasing target identification, accelerated regulatory pathways, advancements in gene therapy, expanded research collaborations, precision medicine approaches.

The growing prevalence of rare diseases is a significant factor propelling the growth of the orphan drugs market. A rare disease is defined as one that affects a small percentage of the population. Treatments for rare diseases often necessitate a cold chain-a temperature-regulated supply chain that is not universally accessible in all countries. Orphan diseases occur infrequently among people (approximately 7 out of 10,000). However, the global prevalence of rare diseases has been on the rise in recent years. For instance, in January 2022, an article from the American Cancer Society indicated that there are around 54,000 new cases of oropharyngeal or oral cancer each year in the USA, with 11,230 fatalities attributed to these cancers. The average age of diagnosis is 63, although these cancers can also affect younger individuals, with just over 20% (1 in 5) of cases occurring in patients under 55. Consequently, the increasing prevalence of rare diseases is driving the growth of the orphan drugs market.

The rising application of orphan drugs in hematology is anticipated to further drive the growth of the orphan drugs market. Hematology is a medical science branch focusing on the study, diagnosis, treatment, and management of disorders related to blood and blood-forming tissues. Orphan drugs offer therapeutic options for rare and orphan blood disorders by targeting specific genetic mutations and cellular processes, reducing the need for blood transfusions, mitigating disease complications, and enhancing the quality of life. For example, in December 2023, the Office of the Assistant Secretary for Planning and Evaluation, a US government department, reported that in 2022, the average cost of a biological product was $174 per prescription, which is 3.7 times higher than the $48 for small-molecule drugs. Notably, 43% of the 1,838 small-molecule drugs had only one manufacturer, accounting for 65% of total expenditures. Therefore, the increasing application of orphan drugs in hematology is expected to drive the growth of the orphan drugs market.

The approval of biological orphan drugs for multiple indications emerges as a significant trend propelling the growth of the orphan drugs market. Biological drugs, utilized in the treatment of rare diseases such as cancer, exhibit fewer side effects and are prevalent in the developed world where these diseases have a high incidence rate. An illustration of this trend is observed in the engagement of biological orphan drug expert Frederick D. Sancilio, Ph.D., by Cardax, Inc., to spearhead the company's biological orphan drug development program. Companies are strategically acquiring biological orphan drugs to enhance their commercial product portfolio and increase revenue.

Leading companies in the orphan drugs market are concentrating on obtaining product approvals for therapies like CAR T-cell therapy to address the urgent needs associated with rare diseases. This strategy not only improves patient outcomes but also takes advantage of regulatory incentives for innovative treatments. CAR T-cell therapy is a personalized form of immunotherapy that involves modifying a patient's T cells to specifically target and attack cancer cells, demonstrating significant efficacy in treating certain blood cancers. For example, in March 2024, Cabaletta Bio, a US-based biotechnology firm, received FDA-granted orphan drug designation for CABA-201. CABA-201 is an investigational CAR T-cell therapy aimed at CD19-positive B-cells, intended to induce durable remission in autoimmune diseases such as systemic sclerosis. Its potential advantages include a targeted treatment approach, a favorable safety profile, and the possibility of long-lasting effects from a single infusion.

In May 2024, Sanofi S.A., a France-based pharmaceutical company that develops, discovers, and delivers medicines and vaccines, acquired Inhibrx Inc. for $1.7 billion. Through this acquisition, Sanofi aims to strengthen its rare disease pipeline by focusing on alpha-1 antitrypsin deficiency and addressing the unmet medical needs of this underserved patient population. Inhibrx is a US-based biotechnology firm dedicated to developing novel therapies, including orphan drugs, to meet the unmet medical needs associated with rare diseases.

Major companies operating in the orphan drugs market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Farbenfabriken Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Applied Molecular Genetics Inc., Novo Nordisk A/S, Merck & Co. KG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., CSL Limited, Biogen Inc., Celgene Corporation, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Grifols SA, Alexion Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Aegerion Pharmaceuticals Inc., Sankyo Co. Ltd.

North America was the largest region in the global orphan drugs market in 2024. Middle East is expected to be the fastest growing region in the orphan drugs market report during the forecast period. The regions covered in the orphan drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the orphan drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The orphan drugs market consists of sales of ivacaftor and alglucerase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orphan Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on orphan drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orphan drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The orphan drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy Area: Oncology; Blood; Central Nervous System; Endocrine; Cardiovascular; Respiratory; Immunomodulatory
2) By Diseases Type: Oncology; Hematology; Neurology; Cardiovascular; Other Disease Types
3) By Drug Type: Biological; Non-Biological
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Sales
Subsegments:
1) By Oncology: Targeted Therapies; Chemotherapy Agents; Immunotherapy Drugs; Hormonal Therapies
2) By Blood: Hematopoietic Growth Factors; Coagulation Factor Concentrates; Treatments for Rare Blood Disorders
3) By Central Nervous System: Medications for Rare Neurological Disorders; Antiepileptic Drugs for Rare Epilepsy Syndromes; Treatments for Rare Neurodegenerative Diseases
4) By Endocrine: Hormonal Replacement Therapies; Treatments for Rare Endocrine Disorders
5) By Cardiovascular: Medications for Rare Cardiovascular Conditions; Treatments for Rare Genetic Heart Disorders
6) By Respiratory: Therapies for Rare Respiratory Diseases; Medications for Rare Allergic Conditions
7) By Immunomodulatory: Treatments for Rare Autoimmune Disorders; Immunotherapies for Rare Inflammatory Conditions
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann-La Roche Ltd.; Farbenfabriken Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33014

1. Executive Summary

2. Orphan Drugs Market Characteristics

3. Orphan Drugs Market Trends And Strategies

4. Orphan Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Orphan Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Orphan Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Orphan Drugs Market Growth Rate Analysis
5.4. Global Orphan Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Orphan Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Orphan Drugs Total Addressable Market (TAM)

6. Orphan Drugs Market Segmentation

6.1. Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Blood
Central Nervous System
Endocrine
Cardiovascular
Respiratory
Immunomodulatory
6.2. Global Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Hematology
Neurology
Cardiovascular
Other Diesease Types
6.3. Global Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biological
Non-Biological
6.4. Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Sales
6.5. Global Orphan Drugs Market, Sub-Segmentation Of Oncology, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapies
Chemotherapy Agents
Immunotherapy Drugs
Hormonal Therapies
6.6. Global Orphan Drugs Market, Sub-Segmentation Of Blood, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hematopoietic Growth Factors
Coagulation Factor Concentrates
Treatments for Rare Blood Disorders
6.7. Global Orphan Drugs Market, Sub-Segmentation Of Central Nervous System, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications for Rare Neurological Disorders
Antiepileptic Drugs for Rare Epilepsy Syndromes
Treatments for Rare Neurodegenerative Diseases
6.8. Global Orphan Drugs Market, Sub-Segmentation Of Endocrine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hormonal Replacement Therapies
Treatments for Rare Endocrine Disorders
6.9. Global Orphan Drugs Market, Sub-Segmentation Of Cardiovascular, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications for Rare Cardiovascular Conditions
Treatments for Rare Genetic Heart Disorders
6.10. Global Orphan Drugs Market, Sub-Segmentation Of Respiratory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapies for Rare Respiratory Diseases
Medications for Rare Allergic Conditions
6.11. Global Orphan Drugs Market, Sub-Segmentation Of Immunomodulatory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Treatments for Rare Autoimmune Disorders
Immunotherapies for Rare Inflammatory Conditions

7. Orphan Drugs Market Regional And Country Analysis

7.1. Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Orphan Drugs Market

8.1. Asia-Pacific Orphan Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Orphan Drugs Market

9.1. China Orphan Drugs Market Overview
9.2. China Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Orphan Drugs Market

10.1. India Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Orphan Drugs Market

11.1. Japan Orphan Drugs Market Overview
11.2. Japan Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Orphan Drugs Market

12.1. Australia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Orphan Drugs Market

13.1. Indonesia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Orphan Drugs Market

14.1. South Korea Orphan Drugs Market Overview
14.2. South Korea Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Orphan Drugs Market

15.1. Western Europe Orphan Drugs Market Overview
15.2. Western Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Orphan Drugs Market

16.1. UK Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Orphan Drugs Market

17.1. Germany Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Orphan Drugs Market

18.1. France Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Orphan Drugs Market

19.1. Italy Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Orphan Drugs Market

20.1. Spain Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Orphan Drugs Market

21.1. Eastern Europe Orphan Drugs Market Overview
21.2. Eastern Europe Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Orphan Drugs Market

22.1. Russia Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Orphan Drugs Market

23.1. North America Orphan Drugs Market Overview
23.2. North America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Orphan Drugs Market

24.1. USA Orphan Drugs Market Overview
24.2. USA Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Orphan Drugs Market

25.1. Canada Orphan Drugs Market Overview
25.2. Canada Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Orphan Drugs Market

26.1. South America Orphan Drugs Market Overview
26.2. South America Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Orphan Drugs Market

27.1. Brazil Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Orphan Drugs Market

28.1. Middle East Orphan Drugs Market Overview
28.2. Middle East Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Orphan Drugs Market

29.1. Africa Orphan Drugs Market Overview
29.2. Africa Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Orphan Drugs Market, Segmentation By Diseases Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Orphan Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Orphan Drugs Market Competitive Landscape And Company Profiles

30.1. Orphan Drugs Market Competitive Landscape
30.2. Orphan Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Farbenfabriken Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Orphan Drugs Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Bristol-Myers Squibb Co.
31.3. AstraZeneca plc
31.4. GlaxoSmithKline plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Eli Lilly and Company
31.7. Gilead Sciences Inc.
31.8. Applied Molecular Genetics Inc.
31.9. Novo Nordisk A/S
31.10. Merck & Co. KG
31.11. AbbVie Inc.
31.12. Teva Pharmaceutical Industries Ltd.
31.13. Regeneron Pharmaceuticals Inc.
31.14. CSL Limited
31.15. Biogen Inc.

32. Global Orphan Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Orphan Drugs Market

34. Recent Developments In The Orphan Drugs Market

35. Orphan Drugs Market High Potential Countries, Segments and Strategies

35.1 Orphan Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Orphan Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Orphan Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer